CopyMark Law Group
4.9/5
Drawing for CYTOPE

USPTO serial 79380759

CYTOPE

Reviewed by CopyMark Law Group

Reg. 7646529Status 700Registered
Filing date
Status date
Registration date
Jan 14, 2025
Examiner
EULIN, INGRID C
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with CYTOPE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tore T. DeBella

Tore T. DeBella Faegre Drinker Biddle & Reath LLP1500 K Street, NWSuite 1100Washington, DC 20005

Goods and services

ClassDescriptionStatusFirst use
005Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetesACTIVE—
042Research and development in the pharmaceutical and biotechnology fieldsACTIVE—
045Licensing of intellectual property in the field of biotechnologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 9, 2026CHLDCHANGE OF OWNER RECEIVED FROM IB—
Mar 26, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 8, 2025FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 22, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 22, 2025FIMPFINAL DISPOSITION PROCESSED—
Apr 14, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 29, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 11, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 11, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 14, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 14, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 26, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 26, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 20, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 18, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 17, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 17, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 17, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 17, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 17, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 10, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 10, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 10, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 19, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 30, 2024RFNTREFUSAL PROCESSED BY IB—
Apr 11, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 11, 2024RFRRREFUSAL PROCESSED BY MPU—
Mar 23, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 23, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 20, 2024DOCKASSIGNED TO EXAMINER—
Oct 17, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 13, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 12, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance